Ser25
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser25  -  PAI-RBP1 (human)

Site Information
DQLFDDEsDPFEVLk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454209

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 )
Disease tissue studied:
bone cancer ( 28 ) , osteosarcoma ( 28 ) , breast cancer ( 4 , 9 , 15 , 16 ) , breast ductal carcinoma ( 9 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , leukemia ( 18 , 36 , 37 ) , acute myelogenous leukemia ( 18 ) , chronic myelogenous leukemia ( 36 , 37 ) , lung cancer ( 7 , 16 , 25 ) , non-small cell lung cancer ( 16 ) , non-small cell lung adenocarcinoma ( 7 ) , lymphoma ( 10 ) , Burkitt's lymphoma ( 10 ) , follicular lymphoma ( 10 ) , mantle cell lymphoma ( 10 ) , neuroblastoma ( 14 ) , ovarian cancer ( 9 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 30 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 38 ) , 293E (epithelial) ( 22 ) , 786-O (renal) ( 5 ) , 786-O (renal) [VHL (human), transfection] ( 5 ) , A498 (renal) ( 27 ) , BJAB (B lymphocyte) ( 10 ) , breast ( 2 , 9 ) , BT-20 (breast cell) ( 16 ) , BT-474 (breast cell) ( 4 ) , CL1-0 (pulmonary) ( 25 ) , CL1-1 (pulmonary) ( 25 ) , CL1-2 (pulmonary) ( 25 ) , CL1-5 (pulmonary) ( 25 ) , DG75 (B lymphocyte) ( 26 ) , FL-18 (B lymphocyte) ( 10 ) , FL-318 (B lymphocyte) ( 10 ) , H2009 (pulmonary) ( 16 ) , H2077 (pulmonary) ( 16 ) , H2887 (pulmonary) ( 16 ) , H322 (pulmonary) ( 16 ) , H322M (pulmonary) ( 16 ) , HCC2279 (pulmonary) ( 16 ) , HCC366 (pulmonary) ( 16 ) , HCC78 (pulmonary) ( 16 ) , HCC827 (pulmonary) ( 16 ) , HCT116 (intestinal) ( 31 ) , HeLa (cervical) ( 1 , 8 , 24 , 29 , 32 , 34 , 38 ) , HOP62 (pulmonary) ( 16 ) , JEKO-1 (B lymphocyte) ( 10 ) , Jurkat (T lymphocyte) ( 12 , 19 , 20 , 21 , 23 , 33 ) , K562 (erythroid) ( 13 , 29 , 35 , 36 , 37 ) , KG-1 (myeloid) ( 18 ) , LCLC-103H (pulmonary) ( 16 ) , liver ( 11 ) , LOU-NH91 (squamous) ( 16 ) , MDA-MB-468 (breast cell) ( 16 ) , NB10 (neural crest) ( 14 ) , NCEB-1 (B lymphocyte) ( 10 ) , NCI-H1395 (pulmonary) ( 16 ) , NCI-H1568 (pulmonary) ( 16 ) , NCI-H2030 (pulmonary) ( 16 ) , NCI-H2172 (pulmonary) ( 16 ) , NCI-H460 (pulmonary) ( 16 , 31 ) , NCI-H647 (pulmonary) ( 16 ) , NPC (neural crest) ( 14 ) , OCI-ly1 (B lymphocyte) ( 10 ) , ovary ( 9 ) , PC9 (pulmonary) ( 7 ) , PC9-IR (pulmonary) ( 7 ) , Raji (B lymphocyte) ( 10 ) , RAMOS (B lymphocyte) ( 10 ) , REC-1 (B lymphocyte) ( 10 ) , SKBr3 (breast cell) ( 15 ) , SU-DHL-4 (B lymphocyte) ( 10 ) , U2OS (bone cell) ( 28 ) , UPN-1 (B lymphocyte) ( 10 ) , WM239A (epidermal) ( 6 )

Upstream Regulation
Treatments:
AZD1152 ( 24 ) , BI2536 ( 24 ) , EGF ( 1 ) , lapatinib ( 15 ) , ZM447439 ( 24 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

6

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

7

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

8

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

9

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

10

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

11

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

12

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

13

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

14

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

15

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

16

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

17

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

18

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

19

Mulhern D (2012) CST Curation Set: 13339; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

20

Mulhern D (2012) CST Curation Set: 13340; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

21

Mulhern D (2011) CST Curation Set: 12709; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

22

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

23

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

24

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

25

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

26

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

27

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

28

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

29

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

30

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

31

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

32

Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20
19351860   Curated Info

33

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

34

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

35

Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

36

Stokes M (2008) CST Curation Set: 4389; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

37

Stokes M (2008) CST Curation Set: 4390; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

38

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info